Nature Reviews Cancer

Papers
(The H4-Index of Nature Reviews Cancer is 77. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Linking pancreatic renewal and cancer initiation1366
Computing brain metastasis impact1153
Digging for treasures in the tumour interactome961
INVADEseq to study the intratumoural microbiota at host single-cell resolution848
An inhospitable site509
Fructose takes a detour to feed cancer501
Emerging strategies to investigate the biology of early cancer467
Artificial intelligence in cancer research, diagnosis and therapy453
Combinatorial strategies to target RAS-driven cancers428
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment407
Oncofetal reprogramming in tumour development and progression370
Mapping the prostate cell family tree369
How medical anthropology can contribute to cancer research324
Tertiary lymphoid structures as hubs of antitumour immunity312
Author Correction: Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma306
Connie J. Eaves (1944–2024)286
The recruitment of metastasis-associated monocytes280
Antihistamines boost immunotherapy271
Fighting cancer with fat264
Beyond genetics: driving cancer with the tumour microenvironment behind the wheel259
Translating premalignant biology to accelerate non-small-cell lung cancer interception252
Epithelial and stromal co-evolution and complicity in pancreatic cancer248
The role of CRAF in cancer progression: from molecular mechanisms to precision therapies246
Targeting transcription cycles in cancer240
Context-dependent functions of pattern recognition receptors in cancer235
No mutation, tumour initiation218
Impersonating neurons216
Under pressure214
Nanoreceptors take down mutant p53213
Moonlighting functions of glucose metabolic enzymes and metabolites in cancer208
Defining a ‘cells to society’ research framework for appendiceal tumours200
Measuring HLA disruption using MHC Hammer198
Remodelling of the tumour microenvironment by the kallikrein-related peptidases194
Gut microbes produce novel genotoxic metabolites191
Tumour EVPs disrupt liver function187
Dendritic cells rise and shine185
Removing barriers to address sex differences in anticancer drug toxicity179
Persistence is key172
Thelpers? More like Ttroublemakers171
Tumour–host interactions through the lens of Drosophila160
Natural killer cells in antitumour adoptive cell immunotherapy155
3D bioprinted cancer models: from basic biology to drug development149
How chemokines organize the tumour microenvironment148
Cancer stem cell–immune cell crosstalk in tumour progression148
B-ring sterols to the rescue145
Points of entry for tumour-infiltrating lymphocytes145
In-depth organoid profiling of pancreatic cancer144
Identifying spatial cellular structures with SPACE-GM144
Bone voyage: immune crosstalk sets sail144
Visualizing intratumoural heterogeneity with EpicMIBI140
Leveraging the replication stress response to optimize cancer therapy135
Un-Fair Skin: racial disparities in acral melanoma research134
Metabolic interplays between the tumour and the host shape the tumour macroenvironment133
The path to leptomeningeal metastasis132
Linking cell mechanical memory and cancer metastasis131
Dynamics and specificities of T cells in cancer immunotherapy128
The plasticity of mRNA translation during cancer progression and therapy resistance120
In situ decellularization of tissues to resolve the tumour-associated matrix119
Deciphering the cancer genome and epigenome112
Encoding spatial tumour dynamics with Starfysh111
Understanding and addressing race disparities in childhood cancer outcomes111
Taming TAMs in brain metastases108
The link between vitamin D and prostate cancer106
Race influences the tumour microbiome106
Don’t blame the messenger: lessons learned for cancer mRNA vaccines during the COVID-19 pandemic101
Targeted protein degradation for cancer therapy97
Polygenic scores in cancer95
Acetyl-CoA metabolism in cancer94
RNA splicing dysregulation and the hallmarks of cancer92
Cancer nanomedicine88
Z-nucleic acids give immunotherapy a boost87
Local CAR manufacturing86
Parity modulates epithelial–immune cell communication82
Author Correction: Antibody-based proteomics: fast-tracking molecular diagnostics in oncology82
Right ON target: a new RAS-GTP inhibitor80
Integrative medicine in oncology: redefining the standard of care80
A trojan horse to target spliceosome mutant cells79
0.065948009490967